Advanced Chemotherapy Technologies Revenue and Competitors

Location

$14.9M

Total Funding

Estimated Revenue & Valuation

  • Advanced Chemotherapy Technologies's estimated annual revenue is currently $1.5M per year.(i)
  • Advanced Chemotherapy Technologies's estimated revenue per employee is $125,500
  • Advanced Chemotherapy Technologies's total funding is $14.9M.

Employee Data

  • Advanced Chemotherapy Technologies has 12 Employees.(i)
  • Advanced Chemotherapy Technologies grew their employee count by 0% last year.

Advanced Chemotherapy Technologies's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$9.8M393%N/AN/A
#2
$15.1M607%N/AN/A
#3
$6M240%N/AN/A
#4
$24.8M99-12%N/AN/A
#5
$19.3M778%N/AN/A
#6
$28.1M11220%N/AN/A
#7
$3.8M15-46%N/AN/A
#8
$19.3M774%N/AN/A
#9
$45.4M1814%N/AN/A
#10
$6.8M27N/AN/AN/A
Add Company

What Is Advanced Chemotherapy Technologies?

Advanced Chemotherapy Technologies is a privately held medical technology company focused on groundbreaking chemotherapy delivery solutions for cancers that are difficult to treat with systemic therapy alone. We are currently focusing on the technical design and development of a novel pancreatic cancer drug delivery device, preparing for first in human trials.

keywords:N/A

$14.9M

Total Funding

12

Number of Employees

$1.5M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Advanced Chemotherapy Technologies News

2022-04-19 - Sintilimab versus placebo in combination with chemotherapy ...

... with chemotherapy as first line treatment for locally advanced or ... 22C3 pharmDx assay (Agilent Technologies, Carpinteria, CA, USA).

2022-04-13 - Chemotherapy Devices Market See Incredible Growth 2022 ...

Leading Players Are: Advanced Chemotherapy Technologies, Baxter International, Becton, Dickinson Company, B. Braun, Fresenius Kabi,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1M129%N/A
#2
$1.9M12-25%N/A
#3
N/A12-8%N/A
#4
$1M129%N/A
#5
$2.2M12-66%N/A